Nephrotic Syndrome With Sunitinib-Associated Focal Segmental Glomerulosclerosis in a Patient With Renal Carcinoma: Partial Reversibility After Dose Adjustment: Case Report. REV SEN 2025, 13 (2), 149-156. https://doi.org/10.56867/118.